このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Regeneron Pharmaceuticals 過去の業績

過去基準チェック /26

Regeneron Pharmaceuticalsは、平均年間10.1%の収益成長を遂げていますが、 Biotechs業界の収益は、年間成長しています。収益は、平均年間19.1% 14.4%収益成長率で成長しています。 Regeneron Pharmaceuticalsの自己資本利益率は15.3%であり、純利益率は32%です。

主要情報

10.1%

収益成長率

10.3%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	14.4%
株主資本利益率	15.3%
ネット・マージン	32.0%
次回の業績アップデート	31 Oct 2024

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Recent updates

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31

収支内訳

Regeneron Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:REGN 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	13,489	4,322	2,826	265
31 Mar 24	13,100	3,858	2,719	0
31 Dec 23	13,117	3,954	2,631	0
30 Sep 23	13,097	3,991	2,554	1,938
30 Jun 23	12,671	4,299	2,443	1,938
31 Mar 23	12,370	4,183	2,267	0
31 Dec 22	12,173	4,338	2,116	0
30 Sep 22	13,710	5,370	2,015	0
30 Jun 22	14,227	5,687	1,931	0
31 Mar 22	16,508	7,934	1,869	0
31 Dec 21	16,072	8,075	1,825	0
30 Sep 21	13,543	6,996	1,569	0
30 Jun 21	12,384	6,205	1,451	0
31 Mar 21	9,198	4,004	1,384	0
31 Dec 20	8,497	3,513	1,346	0
30 Sep 20	7,938	3,156	1,459	0
30 Jun 20	7,387	2,984	1,437	0
31 Mar 20	7,013	2,279	1,383	0
31 Dec 19	6,558	2,116	1,342	0
30 Sep 19	6,622	2,144	1,381	0
30 Jun 19	6,542	2,069	1,446	0
31 Mar 19	6,572	2,428	1,517	0
31 Dec 18	5,146	2,444	1,127	0
30 Sep 18	6,365	1,798	1,475	0
30 Jun 18	6,203	1,591	1,412	0
31 Mar 18	6,065	1,428	1,354	0
31 Dec 17	5,872	1,199	1,320	0
30 Sep 17	5,517	1,278	1,236	0
30 Jun 17	5,236	1,155	1,200	0
31 Mar 17	4,979	963	1,185	0
31 Dec 16	4,860	896	1,178	0
30 Sep 16	4,732	797	1,147	0
30 Jun 16	4,649	743	1,087	0
31 Mar 16	4,435	741	969	0
31 Dec 15	4,104	636	839	0
30 Sep 15	3,808	571	719	0
30 Jun 15	3,396	444	653	0
31 Mar 15	3,063	346	575	0
31 Dec 14	2,820	338	519	0
30 Sep 14	2,628	345	426	0
30 Jun 14	2,499	403	380	0
31 Mar 14	2,291	394	355	0
31 Dec 13	2,105	414	346	0
30 Sep 13	1,909	798	305	0

質の高い収益: REGNは高品質の収益を持っています。

利益率の向上: REGNの現在の純利益率 (29.4%)は、昨年(33.8%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: REGNの収益は過去 5 年間で年間12.7%増加しました。

成長の加速: REGNの過去 1 年間の収益成長率 ( 0.5% ) は、5 年間の平均 ( 年間10.1%を下回っています。

収益対業界: REGNの過去 1 年間の収益成長率 ( 0.5% ) Biotechs業界0.5%を上回りませんでした。

株主資本利益率

高いROE: REGNの自己資本利益率 ( 15.3% ) は低いとみなされます。

Regeneron Pharmaceuticals 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Stock: Valuation Now Demands More Growth

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Executive VP exercised options and sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Co-Founder exercised options and sold US$104m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /26